1. Leukemia Cell Cycle Chemical Profiling Identifies the G2-Phase Leukemia Specific Inhibitor Leusin‑1
- Author
-
Xia, Xiaoyu, Lo, Yu-Chen, Gholkar, Ankur A, Senese, Silvia, Ong, Joseph Y, Velasquez, Erick F, Damoiseaux, Robert, and Torres, Jorge Z
- Subjects
Hematology ,Rare Diseases ,Childhood Leukemia ,Cancer ,Pediatric ,Biotechnology ,Orphan Drug ,Pediatric Research Initiative ,Pediatric Cancer ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Antineoplastic Agents ,Apoptosis ,Cell Division ,Cell Line ,Tumor ,Drug Discovery ,Flow Cytometry ,G2 Phase ,Humans ,Leukemia ,Pyridines ,Thiophenes ,Chemical Sciences ,Biological Sciences ,Organic Chemistry - Abstract
Targeting the leukemia proliferation cycle has been a successful approach to developing antileukemic therapies. However, drug screening efforts to identify novel antileukemic agents have been hampered by the lack of a suitable high-throughput screening platform for suspension cells that does not rely on flow-cytometry analyses. We report the development of a novel leukemia cell-based high-throughput chemical screening platform for the discovery of cell cycle phase specific inhibitors that utilizes chemical cell cycle profiling. We have used this approach to analyze the cell cycle response of acute lymphoblastic leukemia CCRF-CEM cells to each of 181420 druglike compounds. This approach yielded cell cycle phase specific inhibitors of leukemia cell proliferation. Further analyses of the top G2-phase and M-phase inhibitors identified the leukemia specific inhibitor 1 (Leusin-1). Leusin-1 arrests cells in G2 phase and triggers an apoptotic cell death. Most importantly, Leusin-1 was more active in acute lymphoblastic leukemia cells than other types of leukemias, non-blood cancers, or normal cells and represents a lead molecule for developing antileukemic drugs.
- Published
- 2019